Electrocardiographic and Biochemical Evidence for the Cardioprotective Effect of Antioxidants in Acute Doxorubicin-Induced Cardiotoxicity in the Beagle Dogs
スポンサーリンク
概要
- 論文の詳細を見る
Doxorubicin (DOX) is a potent antitumor agent, but the cardiotoxicity mediated by the formation of reactive oxygen species limit its clinical use. The present study aims to explore electrocardiographic and biochemical evidence for the cardioprotective effect of two antioxidants, Lycium barbarum polysaccharides (LBP, the main antioxidant in Lycium barbarum) and edaravone (a potent free radical scavenger, EDA) against DOX-induced acute cardiotoxicity in beagle dogs. In this study, male beagle dogs received daily treatment of either LBP (20 mg/kg, per os (p.o.)) or EDA (2 mg/kg, intravenously (i.v.)) for 7 d and then followed by an intravenous injection of DOX (1.5 mg/kg). DOX (15 mg/kg) significantly induced acute cardiotoxicity in dogs characterized by conduction abnormalities (including decreased heart rate, ST segment elevation, QT intervals prolongation, inverted T wave, arrhythmia, and myocardial ischemia) and increased serum creatine kinase (CK) and aspartate aminotrans-ferase (AST). Pretreatment with LBP or EDA effectively alleviated both DOX-associated conduction abnormalities and increased serum CK and AST. Moreover, physiological and serum biochemical evidences demonstrated that EDA is more effective than LBP in alleviating these abnormalities produced by DOX in heart. All these results confirm and extend previous observations in rats concerning the effectiveness of LBP or EDA against DOX-induced cardiomyopathy.
著者
-
Xin Yanfei
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
Zhang Sheng
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
Gu Liqiang
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
Liu Shupeng
Institutes of Biomedical Engineering, Shanghai University
-
Gao Haiyan
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
You Zhenqiang
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
Zhou Guoliang
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
Wen Lei
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
Yu Jian
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
Xuan Yaoxian
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Acade
-
Zhou Guoliang
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Academy of Medical Sciences
-
Yu Jian
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Academy of Medical Sciences
-
Wen Lei
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Academy of Medical Sciences
-
Gu Liqiang
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Academy of Medical Sciences
-
Gao Haiyan
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Academy of Medical Sciences
-
Xuan Yaoxian
State Key Laboratory of Safety Evaluation for New Drugs, Center of Safety Evaluation, Zhejiang Academy of Medical Sciences